Condition: Bronchopulmonary Dysplasia · Sponsor: Meridigen Biotech Co., Ltd.
The clinical study with UMC119-01 is designed to investigate the safety in patients with bronchopulmonary dysplasia ("BPD"). This will be a dose escalation, open-label, single-center study in infants at high risk for BPD.
This description comes directly from the study's public registry record.
Claire Liao, MS · +886-2-8978-7777 · claire.liao@meridigen.com
Joseph Chen · +886-2-8978-7777 · joseph.chen@meridigen.com
Always discuss trial participation with your own doctor first.
| National Chen-Kung University Hospital | Tainan, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03631420